Skip to main content
. Author manuscript; available in PMC: 2017 Nov 20.
Published in final edited form as: Diabetes Res (Fairfax). 2015 Aug 21;1(4):84–91. doi: 10.17140/DROJ-1-115

Figure 3.

Figure 3

Apelin gene therapy on myocardial autophagy. (A) Apelin overexpression significantly upregulated beclin-1 expression compared to WT-STZ mice treated with Ad-β-gal. Knockout of Sirt3 blunted apelin gene therapy-mediated beclin-1 expression in Sirt3 KO-STZ mice (n=3 mice, †P<0.001). (B) Apelin gene therapy significantly enhanced LC3-II expression compared to WT-STZ mice treated with Ad-β-gal. Knockout of Sirt3 blunted apelin-mediated LC3-II expression in Sirt3 KO-STZ mice (n=3 mice, †P<0.001). (C) Immuno-staining of LC3-II levels in the hearts. Measurement of fluorescent density in the heart section showed that Ad-apelin treatment dramatically increased the LC3-II levels compared to Ad-β-gal injection In WT-STZ+MI mice. In contrast, the Ad-apelin and Ad-β-gal treatment did not change the LC3-II levels in Sirt3 KO-STZ+MI mice.